Dear Client,
As part of our ongoing commitment to ensuring the security of your online trading experience, we would like to inform you of our protocol for addressing any suspicious activities observed on your trading account
Should you notice any irregularities or suspect unauthorized access to your account, we kindly request that you take immediate action by following the steps outlined below:
Send an Email Please send an email to stoptrade@acml.in from your registered email ID. In the email, briefly outline the suspicious activity you have observed.
Phone Call Alternatively, you can call us at 07968101000 Ext: 1 from your registered mobile number. This will enable us to address your concerns promptly.
When contacting us, please ensure you provide the following details:
By providing this information, you enable us to swiftly investigate and take appropriate measures to safeguard your account.
Your security and peace of mind are of utmost importance to us, and we appreciate your cooperation in maintaining the integrity of your trading account.
Prior to joining Alembic, Krishnan served as Vice President and CFO at Syngene Scientific Solutions, a subsidiary of Syngene International, since May 2020. During his tenure, he played a crucial role in driving strategy, business finance, mergers & acquisitions, governance and risk management. He has also held key leadership positions at Vodafone and Tata Trusts.
Krishnan brings with him expertise in business finance, M&A, scalable systems implementation, and governance frameworks, along with managing diverse finance teams.
Meanwhile, the company also informed that R. K. Baheti, Director ' Finance and the current CFO, has relinquished his role as CFO effective 7 July 2025. However, he will continue to serve on the board as an executive director, in line with the terms of his appointment.
Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company. It manufactures and markets generic pharmaceutical products all over the world. Its research and manufacturing facilities are approved by regulatory authorities of many developed countries, including the USFDA.
The company's consolidated net profit declined 12% to Rs 156.89 crore despite a 16.7% jump in net sales to Rs 1,769.64 crore in Q4 FY25 over Q4 FY24.
The scrip rose 0.37% to Rs 1,004.20 on the BSE.
Powered by Capital Market - Live News